The UK has one of the strongest and most productive life sciences sectors in the world, generating turnover of over £50 billion. There are nearly 5000 companies in the wider health life science sector (including non-manufacturing and service companies) in the UK. £4.21 billion was spent on pharmaceutical R&D in the UK in 2012, 25% of the total industrial R&D spend and 34% of total manufacturing industry R&D. Harriet Fear, Chief Executive at One Nucleus, shares her thoughts on the Cambridge/London life science and healthcare corridor.
https://international-pharma.com/wp-content/uploads/2015/06/The-Cambridge…pdf.pdf
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
The Cambridge/London Corridor: Its Strength and Impact on the UK – Harriet Fear, One Nucleus
